# NIH Reporter #5R01AG065248-05

Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 Months

**Recipient:** Cognition Therapeutics, Inc.

**Award Amount:** $16,494,670.00
**Ceiling:** $16,494,670.00

**Awarded:** August 25, 2026

**Identifier:** 5R01AG065248-05

The project funds a Phase 2 clinical trial of CT1812, a candidate Alzheimer’s disease therapy, to assess safety and effects on cognition and disease-related biomarkers in early-stage patients.

### Description

A randomized, double-blind, placebo-controlled Phase 2 trial evaluating the safety, tolerability, and efficacy of two doses of CT1812 in patients with early Alzheimer's disease over 18 months.

[View original record](https://reporter.nih.gov/search/a_XEnEpPR0i-06zXlbqcPw/project-details/11380970)
